Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
28
02
2021
accepted:
21
04
2021
revised:
17
04
2021
pubmed:
26
5
2021
medline:
15
7
2021
entrez:
25
5
2021
Statut:
ppublish
Résumé
Coronavirus disease-19 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), represents one of the biggest challenges of 21st century, threatening public health around the globe. Increasing age and presence of co-morbidities are reported risk factors for severe disease and mortality, along with autoimmune diseases (ADs) and immunosuppressive treatments such as haematopoietic stem cell transplantation (HSCT), which are also associated with adverse outcomes. We review the impact of the pandemic on specific groups of patients with neurological, rheumatological, and gastroenterological indications, along with the challenges delivering HSCT in adult and pediatric populations. Moving forward, we developed consensus-based guidelines and recommendations for best practice and quality of patient care in order to support clinicians, scientists, and their multidisciplinary teams, as well as patients and their carers. These guidelines aim to support national and international organizations related to autoimmune diseases and local clinical teams delivering HSCT. Areas of unmet need and future research questions are also highlighted. The waves of the COVID-19 pandemic are predicted to be followed by an "endemic" phase and therefore an ongoing risk within a "new normality". These recommendations reflect currently available evidence, coupled with expert opinion, and will be revised according to necessary modifications in practice.
Identifiants
pubmed: 34031556
doi: 10.1038/s41409-021-01326-6
pii: 10.1038/s41409-021-01326-6
pmc: PMC8143059
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1493-1508Références
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020;324:782–93. https://doi.org/10.1001/jama.2020.12839 .
doi: 10.1001/jama.2020.12839
pubmed: 32648899
Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020;383:1757–66. https://doi.org/10.1056/NEJMcp2009249 .
doi: 10.1056/NEJMcp2009249
pubmed: 32329974
Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383:2451–60. https://doi.org/10.1056/NEJMcp2009575 .
doi: 10.1056/NEJMcp2009575
pubmed: 32412710
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–9. https://doi.org/10.1172/JCI137244 .
doi: 10.1172/JCI137244
pubmed: 32217835
pmcid: 7190990
Ciceri F, Castagna A, Rovere-Querini P, De Cobelli F, Ruggeri A, Galli L, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. 2020;217:108509. https://doi.org/10.1016/j.clim.2020.108509 .
doi: 10.1016/j.clim.2020.108509
pubmed: 32535188
pmcid: 7289745
Jacques FH, Apedaile E. Immunopathogenesis of COVID-19: summary and possible interventions. Front Immunol. 2020;11:564925. https://doi.org/10.3389/fimmu.2020.564925 .
doi: 10.3389/fimmu.2020.564925
pubmed: 33072103
pmcid: 7533543
Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transpl. 2020;55:283–306. https://doi.org/10.1038/s41409-019-0684-0 .
doi: 10.1038/s41409-019-0684-0
Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2017;1:2742–55. https://doi.org/10.1182/bloodadvances.2017010041 .
doi: 10.1182/bloodadvances.2017010041
pubmed: 29296926
pmcid: 5745133
Snowden JA, Panes J, Alexander T, Allez M, Ardizzone S, Dierickx D, et al. Autologous haematopoietic stem cell transplantation (AHSCT) in Severe Crohn’s Disease: a review on behalf of ECCO and EBMT. J Crohns Colitis. 2018;12:476–88. https://doi.org/10.1093/ecco-jcc/jjx184 .
doi: 10.1093/ecco-jcc/jjx184
pubmed: 29325112
Alexander T, Greco R, Snowden JA. Hematopoietic stem cell transplantation for autoimmune disease. Annu Rev Med. 2021;72:215–28. https://doi.org/10.1146/annurev-med-070119-115617 .
doi: 10.1146/annurev-med-070119-115617
pubmed: 33106103
Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2021;72:340–50. https://doi.org/10.1093/cid/ciaa863 .
doi: 10.1093/cid/ciaa863
pubmed: 33501974
Pinana JL, Martino R, Garcia-Garcia I, Parody R, Morales MD, Benzo G, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21. https://doi.org/10.1186/s40164-020-00177-z .
doi: 10.1186/s40164-020-00177-z
pubmed: 32864192
pmcid: 7445734
Minotti C, Tirelli F, Barbieri E, Giaquinto C, Dona D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J Infect. 2020;81:e61–6. https://doi.org/10.1016/j.jinf.2020.04.026 .
doi: 10.1016/j.jinf.2020.04.026
pubmed: 32335173
pmcid: 7179496
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92. https://doi.org/10.1182/blood.2020008824 .
doi: 10.1182/blood.2020008824
pubmed: 33113551
pmcid: 7746126
Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong KL, et al. Clinical features associated with COVID-19 outcome in MM: first results from International Myeloma Society Dataset. Blood. 2020;136:3033–40. https://doi.org/10.1182/blood.2020008150 .
doi: 10.1182/blood.2020008150
pubmed: 33367546
pmcid: 7759145
He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34:1637–45. https://doi.org/10.1038/s41375-020-0836-7 .
doi: 10.1038/s41375-020-0836-7
pubmed: 32332856
Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4:5966–75. https://doi.org/10.1182/bloodadvances.2020003170 .
doi: 10.1182/bloodadvances.2020003170
pubmed: 33278301
pmcid: 7724912
Schoot TS, Kerckhoffs APM, Hilbrands LB, van Marum RJ. Immunosuppressive drugs and COVID-19: a review. Front Pharm. 2020;11:1333. https://doi.org/10.3389/fphar.2020.01333 .
doi: 10.3389/fphar.2020.01333
Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transpl. 2020;55:2071–6. https://doi.org/10.1038/s41409-020-0919-0 .
doi: 10.1038/s41409-020-0919-0
EBMT. EBMT guidelines. https://www.ebmt.org/covid-19-and-bmt .
Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transpl. 2019;54:1525–52. https://doi.org/10.1038/s41409-019-0516-2 .
doi: 10.1038/s41409-019-0516-2
National Institute for Health and Care Excellence Ng. COVID-19 rapid guideline: haematopoietic stem cell transplantation. 2020. https://www.nice.org.uk/guidance/ng164 .
HM Government. COVID Alert Levels. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/884352/slides_-_11_05_2020.pdf .
Stevens RHR, Perera R, Jason Oke J. Should COVID-19 travel quarantine policy be based on apparent new case rates? The Centre for Evidence-Based Medicine. https://www.cebm.net/2020/09/should-covid-19-travel-quarantine-policy-be-based-on-apparent-new-case-rates/ .
NICE guideline. COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services. 2020. https://www.nice.org.uk/guidance/ng179 .
https://royalsociety.org/-/media/policy/projects/set-c/set-covid-19-R-estimates.pdf .
Das J, Sharrack B, Snowden JA. Autologous hematopoietic stem-cell transplantation in neurological disorders: current approach and future directions. Expert Rev Neurother. 2020;20:1299–313. https://doi.org/10.1080/14737175.2020.1820325 .
doi: 10.1080/14737175.2020.1820325
pubmed: 32893698
Marrie RA, Elliott L, Marriott J, Cossoy M, Blanchard J, Tennakoon A, et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology. 2014;83:929–937. https://doi.org/10.1212/WNL.0000000000000753 .
doi: 10.1212/WNL.0000000000000753
pubmed: 25085638
pmcid: 4153848
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77:184–91. https://doi.org/10.1001/jamaneurol.2019.3365 .
doi: 10.1001/jamaneurol.2019.3365
pubmed: 31589278
Sormani MP, Italian Study Group on C-iims. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. 2020;19:481–2. https://doi.org/10.1016/S1474-4422(20)30147-2 .
doi: 10.1016/S1474-4422(20)30147-2
pubmed: 32359409
pmcid: 7191287
Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, et al. Clinical characteristics and outcomes in patients with Coronavirus Disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77:1079–88. https://doi.org/10.1001/jamaneurol.2020.2581 .
doi: 10.1001/jamaneurol.2020.2581
pubmed: 32589189
Sahraian MA, Azimi A, Navardi S, Ala S, Naser Moghadasi A. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020;46:102472. https://doi.org/10.1016/j.msard.2020.102472 .
doi: 10.1016/j.msard.2020.102472
pubmed: 32890817
pmcid: 7456295
Dalla Costa G, Leocani L, Montalban X, Guerrero AI, Sorensen PS, Magyari M, et al. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci. 2020;41:1647–50. https://doi.org/10.1007/s10072-020-04519-x .
doi: 10.1007/s10072-020-04519-x
pubmed: 32617741
pmcid: 7331489
https://msvirtual2020.org/wp-content/uploads/2020/09/SS02.04.pdf . 2020.
Muppidi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, et al. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol. 2020;19:970–1. https://doi.org/10.1016/S1474-4422(20)30413-0 .
doi: 10.1016/S1474-4422(20)30413-0
pubmed: 33212055
pmcid: 7837033
Mantero V, Rigamonti A, Basilico P, Crespi M, Balgera R, Salmaggi A. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role? J Neurol. 2020;267:3465–6. https://doi.org/10.1007/s00415-020-10039-7 .
doi: 10.1007/s00415-020-10039-7
pubmed: 32638109
pmcid: 7339089
Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, et al. COVID-19 in patients with myasthenia gravis. Muscle Nerve. 2020;62:254–8. https://doi.org/10.1002/mus.26918 .
doi: 10.1002/mus.26918
pubmed: 32392389
Mantero V, Rigamonti A, Basilico P, Crespi M, Balgera R, Salmaggi A. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role? J Neurol. 2020. https://doi.org/10.1007/s00415-020-10039-7 .
Abu-Rumeileh S, Garibashvili T, Ruf W, Fangerau T, Kassubek J, Althaus K, et al. Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19. J Neurol Sci. 2020;418:117106. https://doi.org/10.1016/j.jns.2020.117106 .
doi: 10.1016/j.jns.2020.117106
pubmed: 32911389
pmcid: 7462872
Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017;13:391–405. https://doi.org/10.1038/nrneurol.2017.81 .
doi: 10.1038/nrneurol.2017.81
pubmed: 28621766
Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a Randomized Clinical Trial. JAMA. 2019;321:165–74. https://doi.org/10.1001/jama.2018.18743 .
doi: 10.1001/jama.2018.18743
pubmed: 30644983
pmcid: 6439765
Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016;388:576–85. https://doi.org/10.1016/S0140-6736(16)30169-6 .
doi: 10.1016/S0140-6736(16)30169-6
pubmed: 27291994
Burt RK, Balabanov R, Tavee J, Han X, Sufit R, Ajroud-Driss S, et al. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 2020;267:3378–91. https://doi.org/10.1007/s00415-020-10010-6 .
doi: 10.1007/s00415-020-10010-6
pubmed: 32594300
Burt RKBR, Han X, et al. Autologous hematopoietic stem cell transplantation in patients with stiff person syndrome. Neurology. 2021;96:e817–30.
pubmed: 33318163
Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019;93:e1732–41. https://doi.org/10.1212/WNL.0000000000008394 .
doi: 10.1212/WNL.0000000000008394
pubmed: 31578302
pmcid: 6946475
Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party. Mult Scler. 2015;21:189–97. https://doi.org/10.1177/1352458514541978 .
doi: 10.1177/1352458514541978
pubmed: 25078274
Ardura M, Hartley D, Dandoy C, Lehmann L, Jaglowski S, Auletta JJ, et al. Addressing the impact of the Coronavirus Disease 2019 (COVID-19) pandemic on hematopoietic cell transplantation: learning networks as a means for sharing best practices. Biol Blood Marrow Transpl. 2020;26:e147–60. https://doi.org/10.1016/j.bbmt.2020.04.018 .
doi: 10.1016/j.bbmt.2020.04.018
Zamperlini-Netto G, Fernandes JF, Garcia JL, Ribeiro AAF, Camargo LFA, de Moraes Terra C, et al. COVID-19 after hematopoietic stem cell transplantation: report of two children. Bone Marrow Transpl. 2021;56:713–5. https://doi.org/10.1038/s41409-020-01041-8 .
doi: 10.1038/s41409-020-01041-8
Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583–94. https://doi.org/10.1136/annrheumdis-2016-209133 .
doi: 10.1136/annrheumdis-2016-209133
pubmed: 27338776
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45. https://doi.org/10.1136/annrheumdis-2019-215089 .
doi: 10.1136/annrheumdis-2019-215089
pubmed: 30926722
Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713–23. https://doi.org/10.1136/annrheumdis-2020-216924 .
doi: 10.1136/annrheumdis-2020-216924
pubmed: 32220834
Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99. https://doi.org/10.1136/annrheumdis-2019-216655 .
doi: 10.1136/annrheumdis-2019-216655
pubmed: 31969328
Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327–39. https://doi.org/10.1136/annrheumdis-2016-209909 .
doi: 10.1136/annrheumdis-2016-209909
pubmed: 27941129
Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498–506. https://doi.org/10.1016/S0140-6736(11)60982-3 .
doi: 10.1016/S0140-6736(11)60982-3
pubmed: 21777972
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490–8. https://doi.org/10.1001/jama.2014.6368 .
doi: 10.1001/jama.2014.6368
pubmed: 25058083
Sullivan KM, Goldmuntz EA, Furst DE. Autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378:1066–7. https://doi.org/10.1056/NEJMc1801275 .
doi: 10.1056/NEJMc1801275
pubmed: 29539292
Di Benedetto P, Ruscitti P, Cipriani P, Giacomelli R. Haematopoietic stem cell transplantation in systemic sclerosis: challenges and perspectives. Autoimmun Rev. 2020;19:102662. https://doi.org/10.1016/j.autrev.2020.102662 .
doi: 10.1016/j.autrev.2020.102662
pubmed: 32942028
Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007;26:663–70. https://doi.org/10.1007/s10067-006-0441-9 .
doi: 10.1007/s10067-006-0441-9
pubmed: 17186117
Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019;5:e001041. https://doi.org/10.1136/rmdopen-2019-001041 .
doi: 10.1136/rmdopen-2019-001041
pubmed: 31673420
pmcid: 6803008
Benoy S, Traksel R, Verhaegh P, Broen J. COVID-19 in rheumatology outpatient clinics: Dutch mirror image to Lombardy, Italy. Ann Rheum Dis. 2020;annrheumdis-2020-217765. https://doi.org/10.1136/annrheumdis-2020-217765 .
Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med. 2020;383:85–88. https://doi.org/10.1056/NEJMc2009567 .
doi: 10.1056/NEJMc2009567
pubmed: 32348641
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859–66. https://doi.org/10.1136/annrheumdis-2020-217871 .
doi: 10.1136/annrheumdis-2020-217871
pubmed: 32471903
Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502. https://doi.org/10.1016/j.jaut.2020.102502 .
doi: 10.1016/j.jaut.2020.102502
pubmed: 32527675
pmcid: 7832807
Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79:667–8. https://doi.org/10.1136/annrheumdis-2020-217424 .
doi: 10.1136/annrheumdis-2020-217424
pubmed: 32241793
FRSSSCI consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2020;80:527–38. https://doi.org/10.1136/annrheumdis-2020-218310 .
doi: 10.1136/annrheumdis-2020-218310
Papa ND, Sambataro G, Minniti A, Maglione W, Pignataro F, Caminati A, et al. Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20953356. https://doi.org/10.1177/1759720X20953356 .
doi: 10.1177/1759720X20953356
pubmed: 33029203
pmcid: 7522815
Strangfeld A, Schafer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;annrheumdis-2020-219498. https://doi.org/10.1136/annrheumdis-2020-219498 .
Landewe RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79:851–8. https://doi.org/10.1136/annrheumdis-2020-217877 .
doi: 10.1136/annrheumdis-2020-217877
pubmed: 32503854
Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 2. Arthritis Rheumatol. 2020;72:e1–12. https://doi.org/10.1002/art.41437 .
doi: 10.1002/art.41437
pubmed: 32734689
Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14:4–22. https://doi.org/10.1093/ecco-jcc/jjz180 .
doi: 10.1093/ecco-jcc/jjz180
pubmed: 31711158
SECURE-IBD Database. https://covidibd.org/ . Accessed 5 May 2020.
Attauabi M, Poulsen A, Theede K, Pedersen N, Larsen L, Jess T et al. Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease—a Danish prospective population-based cohort study. J Crohns Colitis. 20216;15:540–50. https://doi.org/10.1093/ecco-jcc/jjaa205 .
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 .
doi: 10.1016/S0140-6736(20)30183-5
pubmed: 31986264
pmcid: 7159299
Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021;70:725–32. https://doi.org/10.1136/gutjnl-2020-322539 .
doi: 10.1136/gutjnl-2020-322539
pubmed: 33082265
Queiroz NSF, Regueiro M. Safety considerations with biologics and new inflammatory bowel disease therapies. Curr Opin Gastroenterol. 2020;36:257–64. https://doi.org/10.1097/MOG.0000000000000607 .
doi: 10.1097/MOG.0000000000000607
pubmed: 31895234
Magro F, Rahier JF, Abreu C, MacMahon E, Hart A, van der Woude CJ, et al. Inflammatory Bowel Disease Management during the COVID-19 outbreak: the ten do’s and don’ts from the ECCO-COVID Taskforce. J Crohns Colitis. 2020;14:S798–806. https://doi.org/10.1093/ecco-jcc/jjaa160 .
doi: 10.1093/ecco-jcc/jjaa160
pubmed: 32722754
Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020;94:949–52. https://doi.org/10.1212/WNL.0000000000009507 .
doi: 10.1212/WNL.0000000000009507
pubmed: 32241953
Sullivan M, Bouffet E, Rodriguez-Galindo C, Luna-Fineman S, Khan MS, Kearns P, et al. The COVID-19 pandemic: a rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. Pediatr Blood Cancer. 2020;67:e28409. https://doi.org/10.1002/pbc.28409 .
doi: 10.1002/pbc.28409
pubmed: 32400924
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7. https://doi.org/10.1016/S1470-2045(20)30096-6 .
doi: 10.1016/S1470-2045(20)30096-6
pubmed: 32066541
pmcid: 7159000
Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG, Alexander T, et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in Crohn’s disease: current status and future directions. A review on behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators. Front Immunol. 2018;9:646. https://doi.org/10.3389/fimmu.2018.00646 .
doi: 10.3389/fimmu.2018.00646
pubmed: 29670622
pmcid: 5893785
Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20:615–32. https://doi.org/10.1038/s41577-020-00434-6 .
doi: 10.1038/s41577-020-00434-6
pubmed: 32887954
pmcid: 7472682
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines . Accessed 11 Dec 2020.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;71:2027–34. https://doi.org/10.1093/cid/ciaa344 .
doi: 10.1093/cid/ciaa344
pubmed: 32221519
Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 Coronavirus in humans with COVID-19 Disease and unexposed individuals. Cell. 2020;181:1489–501.e15. https://doi.org/10.1016/j.cell.2020.05.015 .
doi: 10.1016/j.cell.2020.05.015
pubmed: 32473127
pmcid: 7237901
Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183:e114. https://doi.org/10.1016/j.cell.2020.08.017 .
doi: 10.1016/j.cell.2020.08.017
Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e200–12. https://doi.org/10.1016/S1473-3099(18)30600-5 .
doi: 10.1016/S1473-3099(18)30600-5
pubmed: 30744963
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18. https://doi.org/10.1093/cid/cit816 .
doi: 10.1093/cid/cit816
pubmed: 24421306
ASH-ASTCT. COVID-19 and vaccines: frequently asked questions (Version 1.0; last updated October 27). https://www.hematology.org/covid-19/ash-astct-covid-19-and-vaccines# .
Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transpl. 2008;42:637–41. https://doi.org/10.1038/bmt.2008.264 .
doi: 10.1038/bmt.2008.264
Unger JM, Blanke CD, LeBlanc M, Hershman DL. Association of the Coronavirus Disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials. JAMA Netw Open. 2020;3:e2010651. https://doi.org/10.1001/jamanetworkopen.2020.10651 .
doi: 10.1001/jamanetworkopen.2020.10651
pubmed: 32478845
pmcid: 7265094
Waghmare A, Abidi MZ, Boeckh M, Chemaly RF, Dadwal S, El Boghdadly Z, et al. American Society for Transplantation and Cellular Therapy: guidelines for COVID-19 management in hematopoietic cell transplantation and cellular therapy recipients. Biol Blood Marrow Transpl. 2020;26:P1983–94. https://doi.org/10.1016/j.bbmt.2020.07.027 .
Lupo-Stanghellini MT, Messina C, Marktel S, Carrabba MG, Peccatori J, Corti C, et al. Following-up allogeneic transplantation recipients during the COVID-19 pandemic. Lancet Haematol. 2020;7:e564–5. https://doi.org/10.1016/S2352-3026(20)30176-9 .
doi: 10.1016/S2352-3026(20)30176-9
pubmed: 32450053
pmcid: 7255213
Penedo FJ, Oswald LB, Kronenfeld JP, Garcia SF, Cella D, Yanez B. The increasing value of eHealth in the delivery of patient-centred cancer care. Lancet Oncol. 2020;21:e240–51. https://doi.org/10.1016/S1470-2045(20)30021-8 .
doi: 10.1016/S1470-2045(20)30021-8
pubmed: 32359500
pmcid: 7643123
Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep. 2020;10:20191. https://doi.org/10.1038/s41598-020-77093-z .
doi: 10.1038/s41598-020-77093-z
pubmed: 33214648
pmcid: 7677378
Network NCC. NCCN hematopoietic growth factors, short-term recommendations specific to issues with COVID-19 (SARS-CoV-2). Supportive care. https://www.nccn.org/covid-19/ .
Pereira MR PSM, Scully B. Infections in allogeneic stem cell transplantation. In: Principles and practice of transplant infectious diseases. New York, NY: Springer; 2019. https://doi.org/10.1007/978-1-4939-9034-4_11 .
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transpl. 2009;15:1143–238. https://doi.org/10.1016/j.bbmt.2009.06.019 .
doi: 10.1016/j.bbmt.2009.06.019
Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201:805–16. https://doi.org/10.1084/jem.20041679 .
doi: 10.1084/jem.20041679
pubmed: 15738052
pmcid: 2212822
Farge D, Arruda LC, Brigant F, Clave E, Douay C, Marjanovic Z, et al. Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. J Hematol Oncol. 2017;10:21. https://doi.org/10.1186/s13045-016-0388-5 .
doi: 10.1186/s13045-016-0388-5
pubmed: 28103947
pmcid: 5244700
Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012;19:324–35. https://doi.org/10.1097/MOH.0b013e328353bc7d .